Iovance Biotherapeutics, Inc. Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics, Inc.

IOVA

Rank in Stocks #2837
Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical... Iovance Biotherapeutics, Inc., a biotechnology firm currently in the clinical development stage, is committed to discovering and bringing to market cancer immunotherapy solutions. Its core mission involves leveraging the patient's own immune system to effectively combat and eradicate cancerous cells. The company is presently conducting six Phase 2 clinical trials. These include study C-144-01, evaluating its primary experimental compound, lifileucel, for individuals with advanced melanoma. Another trial, C-145-04, is assessing lifileucel's potential for treating cervical cancer that is recurrent, metastatic, or persistent. Additionally, investigational product LN-145 is undergoing evaluation in trial C-145-03 for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. maintains strategic alliances and licensing arrangements with several distinguished entities, including H. Lee Moffitt Cancer Center, M.D. Anderson Cancer Center, Ohio State University, the Centre hospitalier de l'Université de Montreal, Cellectis S.A., and Novartis Pharma AG. Established in 2007, the company was previously known as Lion Biotechnologies, Inc. It adopted its current name, Iovance Biotherapeutics, Inc., in June 2017. Its corporate offices are located in San Carlos, California.
Share Price
$14.72
Market Cap
$6.67B
Change (1 day)
3.58%
Change (1 year)
534.43%
Country
US
Trade Iovance Biotherapeutics, Inc. (IOVA)

Category

Healthcare
Stock split history for Iovance Biotherapeutics, Inc. (IOVA)
Iovance Biotherapeutics, Inc. stock (symbol: IOVA) underwent a total of 2 stock splits.
The most recent stock split occurred on Sep 26, 2013.
One IOVA share bought prior to May 26, 2010 would equal to 0.23999 IOVA shares today.
Stock split list
Year Split Multiple Cumulative Multiple
2013-09-26 1:100 x0.01 x0.23999
2010-05-26 23999:1000 x23.999 x23.999
Stock splits for similar companies or competitors
Company Number of stock splits Cumulative Multiple Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 1 x2
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 0 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 1 x3
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 0 -
CH
Argenx SE Argenx SE
Argenx SE
ARGX.US
 0 -
NL